Collegium Pharmaceutical (COLL) Share-based Compensation (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Share-based Compensation of $15.4 million for Q1 2026, up 45.69% year-over-year from $10.6 million in Q1 2025, and down 48.42% quarter-over-quarter from $29.9 million in Q4 2025.
Collegium Pharmaceutical (COLL) Share-based Compensation (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Share-based Compensation history runs 13 years deep, the most recent figure standing at $15.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 45.69% year-over-year to $15.4 million; the TTM figure through Mar 2026 stood at $69.5 million (up 24.06% YoY), while the FY2025 annual figure was $41.9 million, up 29.34% from the prior year.
- Share-based Compensation for Q1 2026 stood at $15.4 million, down from $29.9 million in the prior quarter.
- The five-year high for Share-based Compensation was $76.7 million in Q2 2025, with the low at -$13.2 million in Q4 2022.
- The 5-year median for Share-based Compensation is $12.9 million (2024), against an average of $22.1 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation plunged 367.92% in 2022, then soared 670.81% in 2024.
- Collegium Pharmaceutical's Share-based Compensation stood at -$13.2 million in 2022, then jumped by 244.44% to $19.0 million in 2023, then retreated by 28.93% to $13.5 million in 2024, then jumped by 121.49% to $29.9 million in 2025, then plunged by 48.42% to $15.4 million in 2026.
- Business Quant data shows COLL's Share-based Compensation at $15.4 million in Q1 2026, $29.9 million in Q4 2025, and $66.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Collegium Pharmaceutical | 889.75 Mn | 740.43 Mn | 110.29 Mn | 9.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.93 Mn |
| Jun 30, 2026 | 9.93 Mn |
| Mar 31, 2026 | 15.43 Mn |
| Mar 31, 2026 | 15.43 Mn |
| Dec 31, 2025 | 29.92 Mn |
| Dec 31, 2025 | 29.92 Mn |
| Sep 30, 2025 | 66.25 Mn |
| Sep 30, 2025 | 66.25 Mn |
| Jun 30, 2025 | 76.71 Mn |
| Jun 30, 2025 | 76.71 Mn |
| Mar 31, 2025 | 10.59 Mn |
| Mar 31, 2025 | 10.59 Mn |
| Dec 31, 2024 | 13.51 Mn |
| Dec 31, 2024 | 13.51 Mn |
| Sep 30, 2024 | 54.17 Mn |
| Sep 30, 2024 | 54.17 Mn |
| Jun 30, 2024 | 52.29 Mn |
| Jun 30, 2024 | 52.29 Mn |
| Mar 31, 2024 | 12.87 Mn |
| Mar 31, 2024 | 12.87 Mn |